Napredna pretraga

Pregled bibliografske jedinice broj: 137696

Ziprasidone Clinical Trials Conducted in Croatia


Uzun, Suzana; Folnegović-Šmalc, Vera; Mimica, Ninoslav; Ljubin, Tajana; Makarić, Gordan; Ivezić, Slađana; Jelačić, Patricia; Vilibić, Maja; Markan-Šošić, Vera
Ziprasidone Clinical Trials Conducted in Croatia // Abstracts for the XIth Biennial Winter Workshop on Schizophrenia Research ; u: Schizophrenia Research 53 (2002) 3(S1) ; B84
Davos, Švicarska, 2002. str. 182-182 doi:10.1016/S0920-9964(01)00381-4 (poster, međunarodna recenzija, sažetak, stručni)


Naslov
Ziprasidone Clinical Trials Conducted in Croatia

Autori
Uzun, Suzana ; Folnegović-Šmalc, Vera ; Mimica, Ninoslav ; Ljubin, Tajana ; Makarić, Gordan ; Ivezić, Slađana ; Jelačić, Patricia ; Vilibić, Maja ; Markan-Šošić, Vera

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Abstracts for the XIth Biennial Winter Workshop on Schizophrenia Research ; u: Schizophrenia Research 53 (2002) 3(S1) ; B84 / - , 2002, 182-182

Skup
Biennial Winter Workshop on Schizophrenia Research (11 ; 2002)

Mjesto i datum
Davos, Švicarska, 24.02.-01.03.2002

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Ziprasidone ; clinical trials ; Croatia

Sažetak
Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The initial evidence suggests an effective dosage range of 80–160 mgr day. Clinical trials suggests that the drug is an effective antipsychotic intreating the positive and negative symptoms of schizophrenia. Croatian investigators took part in three studies of ziprasidone. The first study was ziprasidone versus risperidone study and this study evaluate comparative efficacy of ziprasidone versus risperidone in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder ZIP-NY-97-033. This 12-week double- blind study evaluated 40, 60, and 80 mg ziprasidone and risperidon bid (N = 34).The second study which we took part was a ZIP-NY-98-035 open extension study evaluatingthe safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed previous ziprasidone study (N = 22). Ziprasidone was initiated at dose of 40 mgbid for days 1 and 2. Dosage was subsequently adjusted within the range 40–80 mg bid according to clinical status. The third study was ziprasidone versus olanzapine in the treatment of chronic schizophrenia or schizoaffective disorder: a 1-year double blind study ZIP-NY-97-002 (N = 20). Although final analyses is not yet done, we can conclude that our experience with ziprasidone trough above mentioned studies confirms efficacy and safety of ziprasidone.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
0123004

Ustanove
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati